Abstract: An amorphous form of dezocine analogue hydrochloride is represented by formula (II). An X-ray powder diffraction spectrum of the amorphous form is shown in FIG. 1.

Abstract: The present invention relates to a crystal form and an amorphous form of dezocine analogue hydrochloride, and in particularly, to a crystal form of a compound represented by formula (I) and an amorphous form of a compound represented by formula (II). An X-ray powder diffraction spectrum of the crystal form comprises characteristic peaks at 2? values of 13.1°±0.2°, 16.8±0.2°, and 18.5±0.2°, and an X-ray powder diffraction spectrum of the amorphous form is shown in FIG. 1.

Abstract: Disclosed are a method for preparing an imidazole derivative and crystal form A and crystal form B thereof, and also disclosed is a method for preparing a compound of formula (I) and an intermediate thereof.

Abstract: Disclosed are a sustained release suspension containing dezocine analogue ester and a preparation method therefor. According to the present invention, an injectable oily auxiliary material which may pharmaceutically serve as a sustained-release depot and an excipient are selected, and micronization technology is used jointly with high pressure homogenization technology and an anti-solvent technique to prepare an injectable long-acting suspension. The main components of the suspension are a compound represented by formula (I), the injectable oil, and the like.

Abstract: Disclosed are a method for preparing an imidazole derivative and crystal form A and crystal form B thereof, and also disclosed is a method for preparing a compound of formula (I) and an intermediate thereof.

Abstract: Disclosed are a method for preparing an imidazole derivative and crystal form A and crystal form B thereof, and also disclosed is a method for preparing a compound of formula (I) and an intermediate thereof.

Abstract: Disclosed in the present disclosure is a Dezocine analog, and particularly disclosed are compounds represented by formula (I), (II) and (III), a pharmaceutically acceptable salt or tautomer thereof.

Abstract: Disclosed are a method for preparing an imidazole derivative and crystal form A and crystal form B thereof, and also disclosed is a method for preparing a compound of formula (I) and an intermediate thereof.

Abstract: Disclosed are a method for preparing an imidazole derivative and crystal form A and crystal form B thereof, and also disclosed is a method for preparing a compound of formula (I) and an intermediate thereof.

Abstract: Disclosed are an antiviral compound and a use thereof in the preparation of a medicament for the treatment of virus infections. Specifically, the present invention relates an imidazole derivative for treating respiratory syncytial virus infection.

Abstract: Disclosed are a method for preparing an imidazole derivative and crystal form A and crystal form B thereof, and also disclosed is a method for preparing a compound of formula (I) and an intermediate thereof.

Abstract: Disclosed are an antiviral compound and a use thereof in the preparation of a medicament for the treatment of virus infections. Specifically, the present invention relates an imidazole derivative for treating respiratory syncytial virus infection.

Abstract: Disclosed are an antiviral compound and a use thereof in the preparation of a medicament for the treatment of virus infections. Specifically, the present invention relates an imidazole derivative for treating respiratory syncytial virus infection.